DLBCL | Clinical

Considering Alternatives to CAR T-Cell Therapy for Primary Refractory DLBCL

June 20, 2022

During a live virtual event, Jakub Svoboda, MD, discussed with participants the choice of therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who would not receive stem cell transplant or chimeric antigen receptor therapy.

Part 2: Selecting a Non-CAR T-Cell Treatment in Third-Line R/R DLBCL

June 06, 2022

During a live virtual event, Jason Westin, MD, discussed with participants the choice of third-line treatment for relapsed/refractory diffuse large B-cell lymphoma for a patient who declines chimeric antigen receptor T-cell therapy.

Roundtable Discussion: Budde Focuses on the Factors Affecting Treatment Decisions in B-cell Lymphoma

June 04, 2022

During a Targeted Oncology case-based event, Elizabeth Budde, MD, PhD, discussed with participants the case of a patient with relapsed/refractory diffuse large B-cell lymphoma who was not eligible for stem cell transplant and declined chimeric antigen receptor T-cell therapy.